NDRA vs. SSKN, CTCX, QTI, BTCY, AEMD, CHEK, ICU, POAI, NURO, and CUTR
Should you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include STRATA Skin Sciences (SSKN), Carmell (CTCX), QT Imaging (QTI), Biotricity (BTCY), Aethlon Medical (AEMD), Check-Cap (CHEK), SeaStar Medical (ICU), Predictive Oncology (POAI), NeuroMetrix (NURO), and Cutera (CUTR). These companies are all part of the "medical equipment" industry.
ENDRA Life Sciences vs.
ENDRA Life Sciences (NASDAQ:NDRA) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
ENDRA Life Sciences has higher earnings, but lower revenue than STRATA Skin Sciences. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, STRATA Skin Sciences' average media sentiment score of 1.00 beat ENDRA Life Sciences' score of 0.00 indicating that STRATA Skin Sciences is being referred to more favorably in the news media.
ENDRA Life Sciences currently has a consensus price target of $700,000.00, suggesting a potential upside of 11,647,154.58%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe ENDRA Life Sciences is more favorable than STRATA Skin Sciences.
ENDRA Life Sciences received 13 more outperform votes than STRATA Skin Sciences when rated by MarketBeat users. However, 63.90% of users gave STRATA Skin Sciences an outperform vote while only 62.77% of users gave ENDRA Life Sciences an outperform vote.
ENDRA Life Sciences has a net margin of 0.00% compared to STRATA Skin Sciences' net margin of -28.72%. STRATA Skin Sciences' return on equity of -69.33% beat ENDRA Life Sciences' return on equity.
ENDRA Life Sciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 32.4% of STRATA Skin Sciences shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 39.0% of STRATA Skin Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
STRATA Skin Sciences beats ENDRA Life Sciences on 9 of the 15 factors compared between the two stocks.
Get ENDRA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ENDRA Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:NDRA) was last updated on 1/21/2025 by MarketBeat.com Staff
